Harvesting Health: Advancing Nutrition and Wellness for Moms and Babies (HH)

June 26, 2026 updated by: Dr. Rebecca Seguin-Fowler, Texas A&M University
This is a randomized controlled trial to assess whether a personalized food kit to pregnant women is feasible, improves diet quality, and enhances pregnancy and birth outcomes compared to standard prenatal care.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The goal of this clinical trial is to examine the effects of a personalized food kit on diet quality and pregnancy outcomes in pregnant women. The main questions it aims to answer are:

  • Does receiving the food kit improve the quality of a mother's diet and specified pregnancy outcomes, compared to standard prenatal care?
  • Researchers will compare participants who receive the Harvesting Health Food Kit (intervention group) with those who do not; all participants submit verification that they are receiving or intend to receive standard prenatal care. From an implementation evaluation perspective the study will address logistical issues (frequency, ease of use and utilization) of a personalized food kit in pregnancy.

Participants will:

  • Be randomly assigned to either receive the food kit or not (all participants submit verification that they are receiving or intend to receive standard prenatal care, which is not provided by the study).
  • Attend regular study visits for clinical data collection and complete questionnaires about their diet and health.
  • (Intervention group only) Order and receive and a food kit that can be updated and personalized every two weeks within designated food categories and amounts.

Study Type

Interventional

Enrollment (Estimated)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Texas
      • College Station, Texas, United States, 77840
        • Recruiting
        • Texas A&M AgriLife Research Institute for Advancing Health Through Agriculture
        • Contact:
        • Principal Investigator:
          • Rebecca Seguin-Fowler, PhD, RDN, LD, CSCS
        • Principal Investigator:
          • Erica Bender, MSN, CNM, NP-Ob/Gyn
      • Dallas, Texas, United States, 75252
        • Recruiting
        • Texas A&M AgriLife Research Institute for Advancing Health Through Agriculture
        • Contact:
        • Principal Investigator:
          • Rebecca Seguin-Fowler, PhD, RDN, LD, CSCS
        • Principal Investigator:
          • Erica Bender, MSN, CNM, NP-Ob/Gyn
      • Mansfield, Texas, United States, 76063
        • Recruiting
        • Texas A&M AgriLife Research Institute for Advancing Health Through Agriculture / Methodist Mansfield Medical Center
        • Contact:
        • Principal Investigator:
          • Rebecca Seguin-Fowler, PhD, RDN, LD, CSCS
        • Principal Investigator:
          • Erica Bender, MSN, CNM, NP-Ob/Gyn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Pregnant individuals 7-12 weeks of gestation at the time of enrollment
  • Aged 18-45 years
  • Carrying a singleton pregnancy
  • Able to read and speak in English or Spanish
  • Reside and plan to receive prenatal and postpartum care within the Dallas-Fort Worth (DFW) metropolitan area or College Station area.
  • Willing to travel to Collin, Dallas, Denton, Ellis, Kaufman, Rockwall, or Tarrant counties for in-person data collection visits
  • Willing to receive the food kit from local partners through delivery or in-person pick-up, as applicable
  • Verification of established or planned prenatal care with a prenatal healthcare provider
  • Access to a smartphone
  • Willing and able to provide informed consent

Exclusion Criteria:

  • Diagnosis of pre-existing type 1 diabetes
  • Significant chronic medical conditions that might impact pregnancy outcomes or study participation (e.g., severe hypertension, renal disease)
  • Multiple gestation
  • Fetal anomaly
  • History of bariatric surgery or other conditions that affect nutrient absorption
  • Current eating disorder
  • Current use of exclusionary medications (i.e., systemic steroids or anti-seizure medications)
  • Continued use of weight loss medication
  • Substance use disorder
  • Current or planned enrollment in another intervention study of any type
  • Inability to comply with study procedures (e.g., cognitive impairment, plan to move away before study completion, loss of pregnancy)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1 (Harvesting Health Food Kit Intervention)
For the intervention group, participation in the food kit (distributed every 2 weeks) will begin in the 1st trimester and end with 2-3 kits postpartum (last kit at 6 weeks). Final data collection is scheduled at/around 12 weeks postpartum. Participants choose all of their food kit contents within specified categories and amounts. Participants will also submit verification that they are receiving or intend to receive standard prenatal care (not study provided).
Biweekly food kits contain appropriate quantities of whole fruits, vegetables, whole grains, dairy, protein foods and fats.
No Intervention: Group 2 (Usual care/control)
Control participants will submit verification that they are receiving or intend to receive standard prenatal care (not study provided).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Healthy Eating Index
Time Frame: Baseline to 6 weeks postpartum
Ranging from 0 to 100, a higher Healthy Eating Index {HEI) score indicates a diet rich in healthy components (fruits, vegetables, whole grains) and lower in moderation components (sodium, added sugars, saturated fats). Calculated from 24-hour recalls collected via Nutrition Data System for Research (NDSR).
Baseline to 6 weeks postpartum

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Concentration of Hemoglobin A1C (HbA1C)
Time Frame: Baseline to 6 weeks postpartum
Measures average blood sugar levels over the past 2-3 months, acting as a key diagnostic tool for diabetes and prediabetes.
Baseline to 6 weeks postpartum
Gestational weight gain
Time Frame: Baseline to delivery
Measured in pounds or kilograms. Guidelines suggest 25-35 pounds (lbs) for normal weight, 28-40 lbs for underweight, 15-25 lbs for overweight, and 11-20 lbs for obese individuals.
Baseline to delivery
Blood Concentration of High-Sensitivity C-Reactive Protein (hsCRP)
Time Frame: Baseline to 6 weeks postpartum
Measures very low levels of C-reactive protein to detect chronic inflammation, primarily assessing cardiovascular disease (CVD) risk.
Baseline to 6 weeks postpartum
Postpartum weight retention
Time Frame: Baseline to 6 weeks postpartum
Measured in pounds or kilograms at 6 weeks postpartum.
Baseline to 6 weeks postpartum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rebecca L Seguin-Fowler, PhD, RDN, LD, CSCS, Texas A&M AgriLife Research
  • Principal Investigator: Erica Bender, MSN, CNM, NP-Ob/Gyn, Texas A&M AgriLife Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 22, 2026

Primary Completion (Estimated)

July 31, 2028

Study Completion (Estimated)

July 31, 2028

Study Registration Dates

First Submitted

June 15, 2026

First Submitted That Met QC Criteria

June 15, 2026

First Posted (Actual)

June 22, 2026

Study Record Updates

Last Update Posted (Actual)

June 30, 2026

Last Update Submitted That Met QC Criteria

June 26, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified individual participant data, including quantitative and qualitative human health and behavioral data collected via survey, clinical assessment, and related methods, will be made available to qualified researchers upon request. Data will be shared in open, non-proprietary formats (e.g., .csv for tabular data; .txt/.doc for text/qualitative data) accompanied by a file documenting experimental design, data collection methods, software/versions used for processing, variable/column definitions, and units or abbreviations. No personally identifiable information will be shared. Prior to release, datasets will be reviewed for intellectual property, patent, or proprietary constraints. Access will require execution of a data use agreement, approved manuscript proposal plan with statistical analysis details, and approval by the study's data access committee, which will evaluate requests to balance scientific value with participant privacy and the terms of informed consent.

IPD Sharing Time Frame

Beginning 24 months following publication of the primary outcome and three key secondary outcome papers and for at least 3 years following project completion.

IPD Sharing Access Criteria

Requests will be reviewed by the PIs (Seguin-Fowler, Bender, Shankar) and/or designated data access committee. Researchers must submit a written proposal describing the scientific rationale and intended use, and must agree to a data use agreement governing confidentiality, security, and citation requirements. Approved users will receive deidentified data along with a data dictionary and the study protocol. Users are required to cite the dataset in any resulting peer-reviewed publications. Requests and inquiries should be directed to the study PI or designated contact listed in the trial registry record and associated publications.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnant Women With Singleton Pregnancies

Clinical Trials on Food Kit

Subscribe